XML 67 R54.htm IDEA: XBRL DOCUMENT
v3.20.2

Commitments - Additional Information (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Dec. 02, 2020 | Sep. 30, 2020 | Aug. 31, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Oct. 31, 2016
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Rent expense |  |  |  |  |  | $ 1,500 | $ 1,600 |
Research and development |  |  |  | $ 2,706 | $ 2,359 | $ 7,713 | 7,966 |
Revenue Share Agreement | Oncimmune Limited |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests |  |  |  |  |  | 8.00% |  |
Minimum annual volume percentage thereafter |  |  |  |  |  | 5.00% |  |
Period of escalations of sales |  |  |  |  |  | through the first four years of sales |  |
Revenue share expenses |  |  |  | 0 |  | $ 200 |  |
Bio-Rad License |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Percentage of royalty payments on net revenue |  |  | 2.50% |  |  |  |  |
License expiry date |  |  | 2024-08 |  |  |  |  |
Royalty expense |  |  |  |  |  | 100 | 0 |
AVEO Oncology |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Research and development |  |  |  | $ 300 | $ 700 | $ 1,000 | $ 900 |
AVEO Oncology | Scenario |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Remaining estimated obligation | $ 300 |  |  |  |  |  |  |
AVEO Oncology | NSCLC POC Trial |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Responsible percentage of development and regulatory costs |  |  |  |  |  |  |  | 50.00%
Ficlatuzumab | AVEO Oncology |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Percentage of development and regulatory costs exercised using opt-out right |  | 50.00% |  |  |  |  |  |
Ficlatuzumab | AVEO Oncology | Scenario |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Percentage of royalty payments on net sales | 10.00% |  |  |  |  |  |  |
Percentage of license income generated from licensing | 25.00% |  |  |  |  |  |  |
BDX004 | Ficlatuzumab | AVEO Oncology | POC Clinical Trials |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Responsible percentage of development and regulatory costs |  |  |  |  |  |  |  | 50.00%

X
- Definition License agreement expiry date. + References No definition available. + Details
Name: | bdsx_LicenseAgreementExpiryDate
Namespace Prefix: | bdsx_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum annual volume percentage thereafter. + References No definition available. + Details
Name: | bdsx_MinimumAnnualVolumePercentageThereafter
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of development and regulatory costs. + References No definition available. + Details
Name: | bdsx_PercentageOfDevelopmentAndRegulatoryCosts
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of development and regulatory costs exercised using opt-out right. + References No definition available. + Details
Name: | bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of license income generated from licensing. + References No definition available. + Details
Name: | bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests. + References No definition available. + Details
Name: | bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty payments on net revenue. + References No definition available. + Details
Name: | bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty payments on net sales. + References No definition available. + Details
Name: | bdsx_PercentageOfRoyaltyPaymentsOnNetSales
Namespace Prefix: | bdsx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of escalations of sales. + References No definition available. + Details
Name: | bdsx_PeriodOfEscalationsOfSales
Namespace Prefix: | bdsx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Remaining estimated obligation. + References No definition available. + Details
Name: | bdsx_RemainingEstimatedObligation
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue share expenses. + References No definition available. + Details
Name: | bdsx_RevenueShareExpenses
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717 + Details
Name: | us-gaap_OperatingLeasesRentExpenseNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bdsx_BDX004Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_POCClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |